Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-04-23-Speech-1-109"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2007-04-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Advanced therapy medicinal products (debate)2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20070423.17.1-109"2
lpv:hasSubsequent	lp_eu:2007-04-23-Speech-1-1102
lpv:speaker	lp:Johannes Blokland2
lpv:spokenAs	chair_of_the_bureau; IND/DEM (2007-02-13--2008-01-29)3 vice-chair; ENVI (2007-02-01--2009-07-13)3 member; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2004-09-15--2009-07-13)3 member; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2004-09-15--2009-07-13)3 substitute; TRAN (2007-01-31--2009-07-13)3 unknown; ChristenUnie - Staatkundig Gereformeerde Parti (2004-07-20--2009-07-13)3
lpv:translated text	". Mr President, imagine someone who is in financial difficulty and who is racking their brains to find a way of making ends meet. They decide to sell tissue and cells of their body for payment in order to eke out a living. This situation is conceivable if we exclude the ban on the commercialisation of the human body from the scope of this regulation. I would argue in favour of backing the amendment in this respect, not least to remain in line with the Oviedo Treaty and the EU Charter of Fundamental Rights. I am also extremely anxious about the technical scope in the area of medicinal products modifying the human germ line as well as those derived from human-animal hybrids, as these techniques greatly affect human dignity. Moreover, there are major differences in opinion among the various Member States. I therefore hope that we can keep these products outside the scope of this regulation out of continued respect for the dignity of the human body and for the choices of the individual Member States. We would, in my view, also reinforce the principle of subsidiarity by keeping these products outside of the regulation’s scope. Since the regulation's legal basis is Article 95, which deals with the internal market, it appears possible, as the proposal is worded at the moment, for legal entities to bring charges before the Court against a national ban on medicinal products that are authorised at European level and to win their case. This is something that must be avoided."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph